These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Sales from licensed and acquired products to increase by 2013. Goodman M Nat Rev Drug Discov; 2009 Jun; 8(6):443. PubMed ID: 19483704 [No Abstract] [Full Text] [Related]
24. The people vs patents. New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337 [No Abstract] [Full Text] [Related]
25. Patent reform in the US: what's at stake for pharmaceutical innovation? Yancey A; Stewart CN Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544 [TBL] [Abstract][Full Text] [Related]
26. A day late and a few million dollars short. Goldenson D Nat Biotechnol; 2009 Jun; 27(6):538-41. PubMed ID: 19513055 [TBL] [Abstract][Full Text] [Related]
27. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity. Berger JM Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292 [No Abstract] [Full Text] [Related]
28. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS. Curti AM Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145 [No Abstract] [Full Text] [Related]
29. Cost-effectiveness data on biologics needed. Sheridan C; Katsnelson A Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069 [No Abstract] [Full Text] [Related]
31. Policy making on data exclusivity in the European Union: from industrial interests to legal realities. Adamini S; Maarse H; Versluis E; Light DW J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988 [TBL] [Abstract][Full Text] [Related]
32. It is not unethical, though it is often unwise, to override patents. Leventer H Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860 [No Abstract] [Full Text] [Related]
34. Patent term extension: an expensive and unnecessary giveaway. Gore A Health Aff (Millwood); 1982; 1(2):25-33. PubMed ID: 10621692 [No Abstract] [Full Text] [Related]
35. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
36. Mergers in Japan help firms retain own products. Fuyuno I Nat Rev Drug Discov; 2005 May; 4(5):358. PubMed ID: 15902766 [No Abstract] [Full Text] [Related]
37. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues. Schuklenk U Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958 [No Abstract] [Full Text] [Related]
38. Reach-through claims for drug target patents: Rx for pharmaceutical policy. Bohrer RA Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015 [No Abstract] [Full Text] [Related]
39. Patent indicators: a window to pharmaceutical market success. Guo Y; Hu Y; Zheng M; Wang Y Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022 [TBL] [Abstract][Full Text] [Related]
40. Data and market exclusivity for pharmaceuticals in the European Community. Kingham RF; Castle GH Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]